JP7045133B2 - Ｃ５多型を有する患者における補体媒介性疾患の治療に使用するためのオルニトドロス・モウバタ（Ｏｒｎｉｔｈｏｄｏｒｏｓ ｍｏｕｂａｔａ）補体阻害剤 - Google Patents

Ｃ５多型を有する患者における補体媒介性疾患の治療に使用するためのオルニトドロス・モウバタ（Ｏｒｎｉｔｈｏｄｏｒｏｓ ｍｏｕｂａｔａ）補体阻害剤 Download PDF

Info

Publication number
JP7045133B2
JP7045133B2 JP2016571246A JP2016571246A JP7045133B2 JP 7045133 B2 JP7045133 B2 JP 7045133B2 JP 2016571246 A JP2016571246 A JP 2016571246A JP 2016571246 A JP2016571246 A JP 2016571246A JP 7045133 B2 JP7045133 B2 JP 7045133B2
Authority
JP
Japan
Prior art keywords
complement
amino acids
protein
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016571246A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017518316A (ja
JP2017518316A5 (enExample
Inventor
エイチ ウェストン－デービス，ウィン
Original Assignee
ヴォリューション イミュノ ファーマシューティカルズ エスエイ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヴォリューション イミュノ ファーマシューティカルズ エスエイ filed Critical ヴォリューション イミュノ ファーマシューティカルズ エスエイ
Publication of JP2017518316A publication Critical patent/JP2017518316A/ja
Publication of JP2017518316A5 publication Critical patent/JP2017518316A5/ja
Application granted granted Critical
Publication of JP7045133B2 publication Critical patent/JP7045133B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2016571246A 2014-06-06 2015-06-08 Ｃ５多型を有する患者における補体媒介性疾患の治療に使用するためのオルニトドロス・モウバタ（Ｏｒｎｉｔｈｏｄｏｒｏｓ ｍｏｕｂａｔａ）補体阻害剤 Active JP7045133B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1410116.6 2014-06-06
GBGB1410116.6A GB201410116D0 (en) 2014-06-06 2014-06-06 Method of treatment
PCT/EP2015/062742 WO2015185760A1 (en) 2014-06-06 2015-06-08 Ornithodoros moubata complement inhibitor for use in the treatment of complement-mediated diseases in patients with c5 polymorphism

Publications (3)

Publication Number Publication Date
JP2017518316A JP2017518316A (ja) 2017-07-06
JP2017518316A5 JP2017518316A5 (enExample) 2019-11-14
JP7045133B2 true JP7045133B2 (ja) 2022-03-31

Family

ID=51266841

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016571246A Active JP7045133B2 (ja) 2014-06-06 2015-06-08 Ｃ５多型を有する患者における補体媒介性疾患の治療に使用するためのオルニトドロス・モウバタ（Ｏｒｎｉｔｈｏｄｏｒｏｓ ｍｏｕｂａｔａ）補体阻害剤
JP2017563314A Expired - Fee Related JP6767396B2 (ja) 2014-06-06 2015-12-09 急性移植片対宿主病の治療に使用するためのオルニトドロス・モウバタ補体阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017563314A Expired - Fee Related JP6767396B2 (ja) 2014-06-06 2015-12-09 急性移植片対宿主病の治療に使用するためのオルニトドロス・モウバタ補体阻害剤

Country Status (16)

Country Link
US (3) US11052129B2 (enExample)
EP (1) EP3151851B1 (enExample)
JP (2) JP7045133B2 (enExample)
KR (1) KR102439717B1 (enExample)
CN (1) CN106659767B (enExample)
AU (1) AU2015270396B2 (enExample)
BR (1) BR112016028446A2 (enExample)
CA (1) CA2951175A1 (enExample)
DK (2) DK3151851T3 (enExample)
ES (2) ES2906630T3 (enExample)
GB (1) GB201410116D0 (enExample)
IL (1) IL249237B (enExample)
MX (1) MX382757B (enExample)
PL (2) PL3151851T3 (enExample)
RU (1) RU2700932C2 (enExample)
WO (1) WO2015185760A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230074605A (ko) * 2016-11-30 2023-05-30 이케아 서플라이 아게 섬유 블랭크의 3차원 섬유 블록 물품으로의 성형

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201410116D0 (en) * 2014-06-06 2014-07-23 Volution Immuno Pharmaceuticals Sa Method of treatment
WO2016198133A1 (en) * 2015-06-08 2016-12-15 Volution Immuno Pharmaceuticals Sa Ornithodoros moubata complement inhibitor for use in the treatment of acute graft versus host disease
GB201602802D0 (en) * 2016-02-17 2016-03-30 Volution Immuno Pharmaceuticals Sa Method of treatment
JP2019521105A (ja) * 2016-06-07 2019-07-25 ノバルティス アーゲー 補体ｃ５多型を有する患者を治療するための抗ｃ５抗体
JP7153669B2 (ja) * 2017-04-21 2022-10-14 ヴォリューション イミュノ ファーマシューティカルズ エスエイ 瘢痕性眼炎症障害の治療のためのコバーシン
DK3612208T5 (da) 2017-04-21 2024-09-02 Volution Immuno Pharmaceuticals Sa Coversin til behandlingen af autoimmune sygdomme med blisterdannelse
WO2019186084A1 (en) * 2018-03-26 2019-10-03 The University Of Liverpool Anti-complement histones
WO2020053206A1 (en) * 2018-09-10 2020-03-19 Volution Immuno Pharmaceuticals Sa Coversin for use in the treatment of rheumatic diseases
GB201905810D0 (en) * 2019-04-25 2019-06-05 Volution Immuno Pharmaceuticals Sa Method of treatment
GB202218084D0 (en) 2022-12-01 2023-01-18 Volution Immuno Pharmaceuticals Sa Fusion proteins
GB202408081D0 (en) 2024-06-06 2024-07-24 Volution Immuno Pharmaceuticals Sa Methods of removing impurities

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011511632A (ja) 2008-02-05 2011-04-14 ナチュラル・エンバイロンメント・リサーチ・カウンシル エイコサノイドによって媒介される疾患及び症状の治療
JP2012516694A (ja) 2009-02-05 2012-07-26 ナチュラル・エンバイロンメント・リサーチ・カウンシル 補体阻害物質としての改変ｏｍｃｉ

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050054033A9 (en) * 1995-08-30 2005-03-10 Human Genome Sciences, Inc. Methods and compositions for treating and preventing infection using human interferon regulatory factor 3
GB0312619D0 (en) * 2003-06-02 2003-07-09 Evolutec Ltd Complement inhibitors
ATE427356T1 (de) 2003-06-02 2009-04-15 Varleigh Ltd Komplementinhibitoren aus zecken
GB0518443D0 (en) 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
PL2061501T3 (pl) * 2006-09-08 2016-01-29 Volution Immuno Pharmaceuticals Sa Sposób leczenia zaburzeń oddechowych
GB0617734D0 (en) * 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders
JP5840623B2 (ja) 2010-01-08 2016-01-06 ヴォリューション イミュノ ファーマシューティカルズ エスエイ 気道のウイルス感染症の治療に用いるｅｖ５７６
TW201418707A (zh) * 2012-09-21 2014-05-16 Alexion Pharma Inc 補體組分ｃ５拮抗劑之篩選分析
GB201410116D0 (en) 2014-06-06 2014-07-23 Volution Immuno Pharmaceuticals Sa Method of treatment
DK3612208T5 (da) 2017-04-21 2024-09-02 Volution Immuno Pharmaceuticals Sa Coversin til behandlingen af autoimmune sygdomme med blisterdannelse

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011511632A (ja) 2008-02-05 2011-04-14 ナチュラル・エンバイロンメント・リサーチ・カウンシル エイコサノイドによって媒介される疾患及び症状の治療
JP2012516694A (ja) 2009-02-05 2012-07-26 ナチュラル・エンバイロンメント・リサーチ・カウンシル 補体阻害物質としての改変ｏｍｃｉ

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Ｍｏｌｅｃｕｌａｒ Ｉｍｍｕｎｏｌｏｇｙ，１９９５年，Ｖｏｌ．３２， ｎｏ．１６，ｐ．１１８３－１１９５
Ｍｏｌｅｃｕｌａｒ Ｉｍｍｕｎｏｌｏｇｙ，２０１３年，Ｖｏｌ．５６， Ｉｓｓｕｅ ３，ｐ．２６４ ＣＤＴ ３
ＮＥＷ ＥＮＧＬＡＮＤ ＪＯＵＲＮＡＬ ＯＦ ＭＥＤＩＣＩＮＥ，２０１４年 ２月１３日，ＶＯＬ：３７０， ｐ．６３２ － ６３９

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230074605A (ko) * 2016-11-30 2023-05-30 이케아 서플라이 아게 섬유 블랭크의 3차원 섬유 블록 물품으로의 성형

Also Published As

Publication number Publication date
PL3151851T3 (pl) 2022-04-04
ES2906630T3 (es) 2022-04-19
US20180193417A1 (en) 2018-07-12
DK3151851T3 (da) 2022-02-28
CA2951175A1 (en) 2015-12-10
NZ727053A (en) 2023-10-27
RU2700932C2 (ru) 2019-09-24
IL249237B (en) 2020-09-30
RU2016151179A3 (enExample) 2019-01-22
GB201410116D0 (en) 2014-07-23
MX2016016139A (es) 2017-07-28
RU2016151179A (ru) 2018-07-16
MX382757B (es) 2025-03-13
IL249237A0 (en) 2017-02-28
KR20170016893A (ko) 2017-02-14
DK3302519T3 (da) 2022-02-28
EP3151851B1 (en) 2021-12-01
AU2015270396B2 (en) 2020-07-16
WO2015185760A1 (en) 2015-12-10
US20210283221A1 (en) 2021-09-16
EP3151851A1 (en) 2017-04-12
JP6767396B2 (ja) 2020-10-14
CN106659767B (zh) 2022-08-30
JP2018516944A (ja) 2018-06-28
JP2017518316A (ja) 2017-07-06
BR112016028446A2 (pt) 2017-10-24
CN106659767A (zh) 2017-05-10
US20170196936A1 (en) 2017-07-13
AU2015270396A1 (en) 2016-12-15
PL3302519T3 (pl) 2022-04-25
KR102439717B1 (ko) 2022-09-02
US11052129B2 (en) 2021-07-06
ES2906632T3 (es) 2022-04-19

Similar Documents

Publication Publication Date Title
JP7045133B2 (ja) Ｃ５多型を有する患者における補体媒介性疾患の治療に使用するためのオルニトドロス・モウバタ（Ｏｒｎｉｔｈｏｄｏｒｏｓ ｍｏｕｂａｔａ）補体阻害剤
JP5784078B2 (ja) 呼吸器疾患の治療方法
US20240009270A1 (en) Coversin for the treatment of autoimmune blistering diseases
EP3302519B1 (en) Ornithodoros moubata complement inhibitor for use in the treatment of acute graft versus host disease
CN101340926A (zh) 治疗重症肌无力的方法
AU2019468121A1 (en) Method of treatment of hematopoietic stem cell transplant associated thrombotic microangiopathy (HSCT-TMA)
US20200040321A1 (en) Deimmunized lysostaphin and methods of use
NZ727053B2 (en) Ornithodoros moubata complement inhibitor for use in the treatment of complement-mediated diseases in patients with c5 polymorphism
KR20080083204A (ko) Ｈｓｐ ９０ 단백질의 억제제를 포함하는 치료 조성물
US20230181672A1 (en) Aberrant post-translational modifications (ptms) in methyl- and propionic acidemia and a mutant sirtuin (sirt) to metabolize ptms
EP2533794A1 (en) Protein domains and uses therefor
Gang Mechanisms of the Anti-Pneumococcal Function of C-Reactive Protein
EP3921339A2 (en) Targeting cd24-siglec interactions for treating subjects with prediabetes or diabetes

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20170823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180608

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180608

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190702

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20191002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20191002

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200317

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200710

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20200710

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200807

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20200811

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20200911

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20200915

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210413

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20210810

C302 Record of communication

Free format text: JAPANESE INTERMEDIATE CODE: C302

Effective date: 20211101

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211108

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20220208

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20220308

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20220308

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220318

R150 Certificate of patent or registration of utility model

Ref document number: 7045133

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250